Month: May 2020

Columbus, OH, May 11, 2020 (GLOBE NEWSWIRE) — Mettler-Toledo International Inc. (NYSE:MTD) today announced the webcast of its presentation at the UBS Virtual Global Healthcare Conference on Tuesday, May 19, 2020, at 12:30 p.m Eastern Time.  To hear a live webcast of the presentation, visit the investor relations page on the Company’s Web site at www.mt.com/investors.  A replay of the webcast will be available for seven days.METTLER TOLEDO (NYSE: MTD) is a leading global supplier of precision instruments and services. We have strong leadership positions in all of our businesses and believe we hold global number-one market positions in most of them. We are recognized as an innovation leader and our solutions are critical in key R&D, quality control, and manufacturing processes for customers in a wide range of industries including...

WESTLAKE, Texas, May 11, 2020 (GLOBE NEWSWIRE) — Core-Mark Holding Company, Inc. (NASDAQ: CORE), one of the largest marketers of food, fresh and broad-line supply solutions to the convenience retail industry in North America, announced today that it will webcast its presentation from the 2020 BMO Farm to Market Conference on Wednesday May 13, 2020 beginning at 2:00 p.m. Eastern.The live webcast can be accessed at www.core-mark.com.  An archived replay of the presentation will be available shortly after the live event is completed and will remain on Core-Mark’s website for 30 days.Core-MarkCore-Mark is one of the largest marketers of food, fresh and broad-line supply solutions to the convenience retail industry in North America. Founded in 1888, Core-Mark offers a full range of products, marketing programs and technology solutions...

CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) — Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today announced financial results for the first quarter ended March 31, 2020, and provided corporate updates.Recent Program and Corporate HighlightsAnnounced plans to prioritize resources towards advancing its preclinical program, BOXR1030, for the treatment of solid tumor cancers: On March 2nd, Unum announced a corporate restructuring plan to prioritize resources towards advancing its preclinical program, BOXR1030, for the treatment of solid tumor cancers. Unum’s BOXR1030 expresses a glypican-3 (GPC3) targeted CAR and incorporates the novel transgene glutamic-oxaloacetic transaminase 2 (GOT2) to improve T cell function in the solid tumor microenvironment...

First quarter 2020 product revenue increased 95% year-over-year to $11.9 millionNDA for IV tramadol accepted for review by FDA; assigned PDUFA date of October 10, 2020Agreement executed with Columbia University to develop a broad platform technology to effectively deliver novel, proprietary oligonucleotides to bind and directly disable mutant DNA with an initial target of KRAS-driven cancers; platform is also being explored as a potential treatment for coronavirusesNEW YORK, May 11, 2020 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2020.Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer, said, “The first quarter of 2020 was another...

New York, NY, May 11, 2020 (GLOBE NEWSWIRE) — AMCI Acquisition Corp. (the “Company”) is pleased to announce that it has entered into a non-binding letter of intent (the “Letter of Intent”) with an established mining company (the “Third Party”) for an initial business combination. Under the terms of the Letter of Intent, the Company would acquire an attractive portfolio of copper production interests (the “Portfolio”). The Portfolio is underpinned by a long-standing, producing operation located in one of the world’s most productive copper belts, which is forecasted to produce in excess of 50,000 metric tons of copper in 2021. The new copper production focused business will be led by an experienced management team with a world-class development and operating track record. The Company will seek to utilize its initial asset base and financial...

NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) — Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS).Dear Shareholders,In the context of the COVID-19 epidemic and in accordance with Ordinance No. 2020-321 of March 25, 2020, the annual general meeting will take place on June 29, 2020 at 9 AM CET at Cellectis’ headquarters, located at 8, rue de la Croix Jarry, 4th floor, 75013 Paris, France behind closed doors, i.e. without the physical presence of the shareholders.The VoteUnder these conditions, shareholders are invited to vote remotely, prior to the General Meeting, by giving a proxy to the Chairman or by returning the voting form.Exceptionally, we invite not to give a proxy to a third party to represent you at the meeting insofar as the meeting will be held without the physical presence of the shareholders and therefore of any third party...

AUSTIN, Texas, May 11, 2020 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the first quarter of 2020. As of March 31, 2020, MTEM’s cash and investments totaled $108 million, which is expected to fund operations into 2022.“We continue to make meaningful progress at MTEM despite the headwinds that COVID-19 has created for clinical trial site initiation and patient enrollment,” said Eric Poma, Ph.D., Molecular Templates’ Chief Executive Officer and Scientific Officer. “We expect to report interim clinical data this year from our three MT-3724 Phase II studies and our MT-5111...

CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host a KOL symposium with a live Q&A for analysts and investors to reflect on the progress of the T cell therapy landscape and provide an in-depth profile of GEN-011 – Genocea’s neoantigen cell therapy – on Tuesday, May 12th at 12:00 p.m. EDT.Genocea will highlight GEN-011 as a potential best-in-class adoptive T cell therapy designed to improve upon the current limitations of TIL therapy. Genocea will also outline the robust, scalable manufacturing process – PLANET™ – to simplify and expand cancer patient access to treatment.The event will also feature Eric Tran, Ph.D., Assistant Member at the Earle A. Chiles Research Institute in the...

Firdapse® Q1 2020 Net Revenues of $29.1 MillionFirst Quarter 2020 GAAP Net Income of $10.4 MillionCatalyst Withdraws Previous 2020 Revenue Guidance Due to COVID-19 UncertaintiesCatalyst to Host Quarterly Conference Call at 8:30 AM ET TomorrowCORAL GABLES, Fla., May 11, 2020 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today reported financial results for the first quarter ended March 31, 2020 and provided a corporate update.“I am very proud of the way that the entire Catalyst team has quickly responded and adapted in these challenging and unprecedented times to ensure the safety of all employees, while still providing...

VANCOUVER, British Columbia, May 11, 2020 (GLOBE NEWSWIRE) — Allegiant Gold Ltd. (“ALLEGIANT”) (AUAU:  TSX-V) (AUXXF: OTCQX) will be hosting a webcast/conference call on Thursday, May 14 at 11:30 a.m. ET (8:30 a.m. PT) to discuss the state of the junior mining and exploration markets.“Given the recent upswing in the precious metals, there has been a renewed interest in the mining and exploration markets. We are at the very early stage of an emerging bull market in the sector and it is important for investors to get prepared for possibly participating in the next boom cycle,” commented Peter Gianulis, President & CEO of ALLEGIANT.  The call will focus on various aspects of the junior exploration market and will not exceed one hour (including 30 minutes for Q&A).  Topics to be discussed include:Current state of market for...